Michala Jakubíková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michala Jakubíková has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Jiří Piťha
Department of Neurology and Center for Clinical Neuroscience Charles University in Prague First Faculty of Medicine and General University Hospital in Prague Prague Czech Republic
3 shared publicationsA. Evoli
Institute of Neurology, Catholic University, Rome, Italy
2 shared publicationsA. Kostera-Pruszczyk
Department of Neurology, Medical University of Warsaw, Poland
2 shared publicationsA. Maniaol
Norway Department of Neurology, Ullevaal University Hospital, Oslo, Norway
2 shared publicationsA. Vaknin
Hadassah Hebrew University Medical Center, Jerusalem, Israel
2 shared publications- Anthony Behin
Institut de Myologie, Centre de Référence de Pathologie Neuromusculaire Paris-Est, GH Pitié-Salpêtrière, Paris, France
2 shared publications
Latest Publications
- Open Access
- 9 November 2021
- Published by Wiley in European Journal of Neurology
- Vol. 29 (1) , E7-E8
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
- 9 November 2021
- Published by Wiley in European Journal of Neurology
- Vol. 29 (1) , E7-E8
Open AccessPredictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
- Open Access
- 3 June 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (10) , 3418-3425
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
Background and purpose: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness, older age and long‐term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID‐19 in MG patients and risk of MG exacerbation during COVID‐19.Methods: We evaluated clinical features and outcomes after COVID‐19 in 93 MG patients.Results: Thirty‐five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID‐19. Higher forced vital capacity (FVC) values tested before COVID‐19 were shown to be protective against severe infection (95% CI 0.934–0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047–1.232). Long‐term chronic corticosteroid treatment worsened the course of COVID‐19 in MG patients (95% CI 1.784–111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448–2.935), mycophenolate mofetil (95% CI 0.91–12.515) and ciclosporin (95% CI 0.029–2.212) did not influence the course of COVID‐19. MG patients treated with rituximab had a high risk of death caused by COVID‐19 (95% CI 3.216–383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885–10.87).Conclusions: As the most important predictors of severe COVID‐19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long‐term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.
- 3 June 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (10) , 3418-3425
Open AccessPredictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
Background and purpose: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness, older age and long‐term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID‐19 in MG patients and risk of MG exacerbation during COVID‐19.Methods: We evaluated clinical features and outcomes after COVID‐19 in 93 MG patients.Results: Thirty‐five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID‐19. Higher forced vital capacity (FVC) values tested before COVID‐19 were shown to be protective against severe infection (95% CI 0.934–0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047–1.232). Long‐term chronic corticosteroid treatment worsened the course of COVID‐19 in MG patients (95% CI 1.784–111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448–2.935), mycophenolate mofetil (95% CI 0.91–12.515) and ciclosporin (95% CI 0.029–2.212) did not influence the course of COVID‐19. MG patients treated with rituximab had a high risk of death caused by COVID‐19 (95% CI 3.216–383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885–10.87).Conclusions: As the most important predictors of severe COVID‐19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long‐term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.
- 1 March 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 292, 108-115
Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen
- 1 March 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 292, 108-115
Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen
- 20 August 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 358 (1-2) , 101-106
Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells
- 20 August 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 358 (1-2) , 101-106
Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells
- Open Access
- 1 July 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 284, 10-17
MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study
- 1 July 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 284, 10-17
Open AccessMuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study
- 6 February 2013
- Published by Wiley in Muscle & Nerve
- Vol. 47 (3) , 447-451
Myasthenia gravis, castleman disease, pemphigus, and anti‐phospholipid syndrome
Introduction: Myasthenia gravis is an autoimmune disease marked by neuromuscular transmission failure at the neuromuscular junction. Castleman disease is a rare lymphoproliferative disease characterized by non‐cancerous angiofolicular hyperplasia of lymphatic tissue. Methods and results: We describe a young man with rapid, successive manifestations of myasthenia gravis, a solitary form of Castleman disease, pemphigus vulgaris, and anti‐phospholipid syndrome, which resulted in 2 ischemic cerebrovascular events that caused a severe central neurological deficit. Discussion: We were unable to find a similar case in the literature, but we hypothesize that the temporal concidence of these clinical entities may be related to a common immunological pathway, such as B‐cell activation. Therefore, we treated the patient with an immunosuppressant and anticoagulant treatment, as well as rituximab, a monoclonal antibody therapy against CD20+. Muscle Nerve 47:447‐451, 2013
- 6 February 2013
- Published by Wiley in Muscle & Nerve
- Vol. 47 (3) , 447-451
Myasthenia gravis, castleman disease, pemphigus, and anti‐phospholipid syndrome
Introduction: Myasthenia gravis is an autoimmune disease marked by neuromuscular transmission failure at the neuromuscular junction. Castleman disease is a rare lymphoproliferative disease characterized by non‐cancerous angiofolicular hyperplasia of lymphatic tissue. Methods and results: We describe a young man with rapid, successive manifestations of myasthenia gravis, a solitary form of Castleman disease, pemphigus vulgaris, and anti‐phospholipid syndrome, which resulted in 2 ischemic cerebrovascular events that caused a severe central neurological deficit. Discussion: We were unable to find a similar case in the literature, but we hypothesize that the temporal concidence of these clinical entities may be related to a common immunological pathway, such as B‐cell activation. Therefore, we treated the patient with an immunosuppressant and anticoagulant treatment, as well as rituximab, a monoclonal antibody therapy against CD20+. Muscle Nerve 47:447‐451, 2013
- Open Access
- 1 January 2013
- Published by Elmer Press, Inc. in Journal of Neurology Research
- Vol. 3 (2)
Mycotic Spondylitis Caused by Cladosporium Cladosporides: A Case Report
- 1 January 2013
- Published by Elmer Press, Inc. in Journal of Neurology Research
- Vol. 3 (2)
Open AccessMycotic Spondylitis Caused by Cladosporium Cladosporides: A Case Report